Clinical studies
Tomorrow's therapies come from today's studies!
We offer a wide range of services from early clinical trials (phase I, first-in-human) to large randomized phase III trials, as well as phase IV and registry studies. We are currently conducting more than 70 clinical trials in oncology, of which an average of 30 are actively recruiting studies. The portfolio includes trials for all solid tumors and lymphomas, in both early and advanced tumor stages.
The team, headed by Prof. Heinz Läubli, Dr. David König and Céline Jenni, comprises 12 employees and is part of the Oncology Department at the University Hospital Basel. This gives patients access to new therapeutic approaches in order to achieve optimal oncological treatment.
If you, as a referring physician or patient, have any questions about a study or possible participation in a study, please send an e-mail to the contact person provided.
Gastrointestinal tumors
Zweite und weitere Linien
MK 5909-005
Eine Phase II Studie zur Bewertung der Sicherheit und Wirksamkeit von Raludotatug Deruxtecan bei Teilnehmern mit gastrointestinalen Krebserkrankungen.
Kontakt: Prof. Viviane Hess
Brain tumors
Glioblastoma
GLUGLIO
A phase IB/II study of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma.
Contact person: Prof. Heinz Läubli
GLIOSUN
A study to evaluate the safety and efficacy of the anti-tumor human antibody cytokine fusion protein L19TNF in combination with standard chemoradiotherapy with temozolomide in patients with newly diagnosed glioblastoma.
Contact person: Dr. Benjamin Thiele
Lung tumors
Small cell lung cancer (SCLC)
ETOP 23-22 RAISE
A phase II study to investigate the effect of niraparib and immunotherapy in patients with SLFN11-positive small cell lung cancer.
Contact person: Dr. David König
DeLLphi-305
A phase III study of tarlatamab in combination with durvalumab versus durvalumab alone in patients with advanced-stage small cell lung cancer after prior chemoimmunotherapy.
Contact person: Dr. Andreas Schmitt
Non-small cell lung cancer (NSCLC)
ETOP 25-23 ADOPT
A phase III study to evaluate the benefit of adjuvant durvalumab treatment after neoadjuvant chemotherapy plus durvalumab in patients with operable stage IIB-IIIB (N2) non-small cell lung cancer.
Contact person: Dr. David König
SGNB6A-002
A phase III study of sigvotatug vedotin versus docetaxel in pretreated non-small cell lung cancer.
Contact person: Dr. Andreas Schmitt
SAKK 16/18
A phase II trial in which radiotherapy is used to enhance the effect of pre-operative (before tumor surgery) immunotherapy in patients with locally advanced non-small cell lung cancer.
Contact person: Dr. David König
PACIFIC-8
A phase III study of durvalumab in combination with domvanalimab versus durvalumab and placebo in patients with locally advanced (stage III), inoperable non-small cell lung cancer whose disease has not progressed after definitive platinum-based radiochemotherapy.
Contact person: Dr. David König
TROPION-Lung 08
A phase III study of Dato-DXd plus pembrolizumab compared to pembrolizumab alone in untreated study participants with advanced or metastatic non-small cell lung cancer with high PD-L1 levels (≥ 50%), without targetable genomic alterations.
Contact person: Dr. Benjamin Thiele
Krascendo 170 Lung
A Phase IB/II study to evaluate the safety and efficacy of GDC-6036 at various doses in combination with other cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRASG12C mutation.
Contact person: Dr. David König
CodeBreak 202
A phase III study of first-line treatment with platinum chemotherapy in combination with sotorasib versus pembrolizumab in PD-L1-negative and KRASG12C-positive advanced/metastatic non-small cell lung cancer.
Contact person: PD Dr. Benjamin Kasenda
BaseTIL-02
A phase II trial of adoptive cell therapy with tumor-infiltrating lymphocytes in patients with non-small cell lung cancer.
Contact person: Dr. David König
Lymphomas (non-Hodgkin's)
NX-5948-301
Eine Phase I Studie zur Bewertung der Sicherheit und Wirksamkeit von NX-5948, einem Bruton-Tyrosinkinase (BTK)-Degrader, bei Patientinnen und Patienten mit rezidivierten/refraktären B-Zell-Malignomen.
Kontakt: PD Dr. Benjamin Kasenda
CA123-1000
Eine Phase I/II Studie mit BMS-986458 allein oder in Kombination mit Anti-Lymphom-Wirkstoffen bei rezidiviertem/refraktärem Non-Hodgkin Lymphom.
Kontakt: Dr. Fatime Krasniqi
Melanomas
TIL-Therapie (hier läuft die Behandlung nicht innerhalb einer Studie sondern über eine befristete Bewilligung)
Eine adoptive Zelltherapie mit tumorinfiltrierenden Lymphozyten und Interleukin-2 bei Patienten mit fortgeschrittenem Melanom.
Kontakt: Prof. Heinz Läubli
IGNYTE-3
Eine Phase III Studie zum Vergleich von Vusolimogene Oderparepvec in Kombination mit Nivolumab vs. Standardbehandlung bei Patienten mit fortgeschrittenem Melanom, deren Krankheit unter einer Anti-PD-1- und einer Anti-CTLA-4-haltigen Therapie fortgeschritten ist.
Kontakt: Dr. Andreas Schmitt
Mesothelioma
eVOLVE-Meso
A phase III study with Volrustomig in combination with chemotherapy compared to chemotherapy alone in inoperable pleural mesothelioma.
Contact person: Dr. David König
Sarcomas
SaLuDo
A phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma.
Contact person: Dr. Fatime Krasniqi
Urogenital tumors
Prostate cancer
ProBio
An outcome-adaptive study with biomarkers in patients with metastatic prostate cancer.
Contact person: Prof. Frank Stenner
Various tumors / Phase I studies
DODEKA
A Phase I study to assess the safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19.
Contact person: Dr. David König
IMC-F106C-101
A Phase I/II study of the safety and efficacy of IMC-F106C as a single agent and in combination with immunotherapy in HLA-A*02:01-positive participants with advanced PRAME-positive cancers.
Contact person: Dr. Anton Oseledchyk
ISCA-CHECK
Safety and modulation of adaptive immunity by Iscador® Qu Viscum Album extract in patients with advanced, recurrent or metastatic cancer treated with immune checkpoint inhibitors.
Contact person: Prof. Mascha Binder